Make Better Decisions

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Mallinckrodt
Teva
Fish and Richardson
Merck
QuintilesIMS
Accenture
Chinese Patent Office
Harvard Business School
Queensland Health

Generated: January 22, 2018

DrugPatentWatch Database Preview

Silvergate Pharms Company Profile

« Back to Dashboard

What is the competitive landscape for SILVERGATE PHARMS, and what generic alternatives to SILVERGATE PHARMS drugs are available?

SILVERGATE PHARMS has four approved drugs.

There are six US patents protecting SILVERGATE PHARMS drugs on SILVERGATE PHARMS drugs in the past three years.

There are seven patent family members on SILVERGATE PHARMS drugs in four countries.

Summary for Silvergate Pharms
International Patents:7
US Patents:6
Tradenames:4
Ingredients:3
NDAs:4

Drugs and US Patents for Silvergate Pharms

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Silvergate Pharms QBRELIS lisinopril SOLUTION;ORAL 208401-001 Jul 29, 2016 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Silvergate Pharms EPANED KIT enalapril maleate FOR SOLUTION;ORAL 204308-001 Aug 13, 2013 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Silvergate Pharms XATMEP methotrexate sodium SOLUTION;ORAL 208400-001 Apr 25, 2017 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Silvergate Pharms XATMEP methotrexate sodium SOLUTION;ORAL 208400-001 Apr 25, 2017 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Silvergate Pharms QBRELIS lisinopril SOLUTION;ORAL 208401-001 Jul 29, 2016 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Silvergate Pharms EPANED KIT enalapril maleate FOR SOLUTION;ORAL 204308-001 Aug 13, 2013 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Silvergate Pharms EPANED enalapril maleate SOLUTION;ORAL 208686-001 Sep 20, 2016 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for SILVERGATE PHARMS drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Powder for Oral Solution 1 mg/mL ➤ Subscribe 6/21/2016

Non-Orange Book US Patents for Silvergate Pharms

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,814,751 Lisinopril formulations ➤ Subscribe
9,808,442 Enalapril formulations ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for Silvergate Pharms Drugs

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

QuintilesIMS
Dow
Novartis
Daiichi Sankyo
Cipla
Cerilliant
Boehringer Ingelheim
Colorcon
Covington

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot